The startup develops pharmaceutical products that utilize a specialized delivery technology to enhance the penetration of active ingredients through the skin and nails. This approach targets skin diseases and infections, providing effective treatment options for both acute and chronic wounds while minimizing antibiotic resistance.
Funding
$76.8M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many topical treatments for skin conditions like eczema and onychomycosis (nail fungus) struggle with effective drug delivery, limiting the penetration of active ingredients to the affected areas. Traditional treatments may also carry risks of side effects or contribute to antibiotic resistance.
Solution
Turn Therapeutics develops pharmaceutical products and medical devices utilizing its proprietary PermaFusion technology to enhance the delivery of active pharmaceutical ingredients through the skin and nails. PermaFusion permanently fuses liquid with oil, enabling deeper penetration with reduced concentrations of active ingredients, which minimizes potential side effects. The company's pipeline includes treatments for eczema that inhibit key immune signals without steroids or needles, and treatments for onychomycosis with high potential efficacy through improved nail bed penetration. Turn Therapeutics aims to provide safer and more effective treatment options for a range of dermatological conditions while minimizing the risk of antibiotic resistance.
Target Audience
The primary target audience includes patients suffering from skin conditions such as eczema, onychomycosis, and other dermatological ailments, as well as the medical professionals who treat them, including dermatologists and podiatrists.
Features
- PermaFusion technology: Patented mixing process that permanently fuses liquid with oil for enhanced topical drug delivery.
- Eczema treatment: Non-steroidal formula that inhibits key immune signals responsible for eczema, including IL-36 and IL-31.
- Onychomycosis treatment: Formula designed to penetrate the nail bed for effective treatment of nail fungus.
- FDA-cleared technology: Platform technology has been cleared by the FDA for multiple indications, demonstrating safety and versatility.
- Data-backed efficacy: Clinical data demonstrates efficacy against a broad range of skin disorders while minimizing insult to delicate human tissue.